Drug details
Koselugo (selumetinib capsules)
type of Antineoplastics MEK Inhibitors
Koselugo (selumetinib) is a kinase inhibitor indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
This drug may have the following side effects:
- nausea,
- rash,
- vomiting,
- diarrhea,
- fever,
- musculoskeletal pain,
- headache,
- itching
- fatigue,
- abdominal pain,
- dry skin,
- acne,
- inflammation of the mouth and lips,
- nail infection, and